Biodesix, Inc. (BDSX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Biodesix, Inc. (BDSX)
Go deeper and ask any question about BDSX
Company Performance
Current Price
as of Sep 13, 2024$1.77
P/E Ratio
N/A
Market Cap
$256.96M
Description
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.
Metrics
Overview
- HQLouisville, CO
- SectorHealth Services
- IndustryMedical/Nursing Services
- TickerBDSX
- Price$1.77-1.67%
Trading Information
- Market Cap$256.96M
- Float52.69%
- Average Daily Volume (1m)95,365
- Average Daily Volume (3m)135,109
- EPS-$0.46
Company
- Revenue$60.90M
- Rev Growth (1yr)50.99%
- Net Income-$10.81M
- Gross Margin78.37%
- EBITDA Margin-38.22%
- EBITDA-$6.85M
- EV$213.87M
- EV/Revenue3.51
- P/EN/A
- P/S3.70